Sobi revenues up 27% in 2nd-qtr 2014
Biotech firm Swedish Orphan Biovitrum (SOBI: SS), has announced total revenues of 662.5 million Swedish kronor ($97 million) for the second quarter of 2014, an increase of 27% on figures from the same period last year.
Boost for generics and Orfadin
Product revenues stood at 475.5 million kronor, up from 371.7 million kronor in the same period last year, and Sobi cites revenues for Key Therapeutic Areas as 316.8 million kronor – an increase of 30%. Its genetics and metabolism division had a particular boost from Orfadin (nitisinone), which saw sales go up 68% on second-quarter 2013 to 139.6 million kronor. This increase is largely attributed to Sobi starting direct sales in North America, after terminating the distribution agreement with Rare Disease Therapeutics from March 31.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze